Expert Interview
A second look: Discussing APG777 from Apogee Therapeutics in atopic dermatitis
Ticker(s): APGEInstitution: Private Practice
- Board-Certified dermatologist practicing cosmetic, medical, surgical and pediatric dermatology.
- Treats 5 patients with DEB and 100 patients with atopic dermatitis each month.
- Served as a sub-investigator for 10 randomized clinical drug trials for atopic dermatitis, psoriasis, systemic lupus erythematosus and cutaneous T-cell lymphoma; investigator for Dupixent’s Phase 2 AD trials.
Do you see your use of Dupixent in AD decreasing anytime soon?
Added By: wilson_adminWhat is the need for something like Dupixent with less frequent dosing?
Added By: wilson_adminHow optimistic are you for APG777?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
